The U.S. Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines such as Ozempic and Mounjaro to warn users in the package leaflet about a possible increased risk of a rare optic-nerve condition. The condition can lead to permanent loss of vision.